Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSL 346

Drug Profile

CSL 346

Alternative Names: 2H10; CSL-346

Latest Information Update: 26 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zenyth Therapeutics
  • Developer CSL; Zenyth Therapeutics
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Fatty acid modulators; Vascular endothelial growth factor B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Diabetic nephropathies
  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 03 May 2019 CSL completes a phase I trial (In volunteers) in Australia (ACTRN12617001554358)
  • 13 Nov 2017 Phase-I clinical trials in Type-2 diabetes mellitus (In volunteers) in Australia (SC) (IV) (ACTRN12617001554358)
  • 10 Feb 2017 Preclinical trials in Diabetic nephropathies in Australia (SC) before February 2017 (9211410; CSL pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top